Izzi-Engbeaya C

ORCID: 0000-0001-7599-0166 · 3 papers in corpus · active 2014-2017
2017
A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial.
Human reproduction (Oxford, England) ·doi:10.1093/humrep/dex253

Study questionCan increasing the duration of LH-exposure with a second dose of kisspeptin-54 improve oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS)?Summary answerA second dose of kisspeptin-54 at 10 h fo…

2015
Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy.
The Journal of clinical endocrinology and metabolism ·doi:10.1210/jc.2015-2332

ContextIn vitro fertilization (IVF) treatment is an effective therapy for infertility, but can result in the potentially life-threatening complication, ovarian hyperstimulation syndrome (OHSS).ObjectiveThis study aimed to investigate whethe…

2014
Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.
The Journal of clinical investigation ·doi:10.1172/jci75730

BackgroundPatients with mutations that inactivate kisspeptin signaling are infertile. Kisspeptin-54, the major circulating isoform of kisspeptin in humans, potently stimulates reproductive hormone secretion in humans. Animal studies suggest…